Coexpression of HER-2/neu and p53 in breast cancer identifies a subset with an aggressive biopathological profile

Tumori

Volumn 92, Issue 5, 2006, Pages 412-415

  Sidoni, Angelo ^a,c   Cavaliere, Antonio ^a   Bellezza, Guido ^a   Del Sordo, Rachele ^a   Angiero, Francesca ^b   Gori, Stefania ^c   Rulli, Antonio ^a   Bucciarelli, Emilio ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c POLICLINICO MONTELUCE   (Italy)

Author keywords

Breast cancer; HER 2 neu; p53; Prognostic factors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; ARTICLE; BREAST CARCINOMA; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC STABILITY; HUMAN; LYMPHOMA; PREVALENCE; PROGNOSIS; PROTEIN EXPRESSION;

EID: 33845264166     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160609200508     Document Type: Article

References (21)

1. Schnitt SJ: Traditional and newer pathologic factors. J Natl Cancer Inst Monogr, 30: 22-26, 2001.
2. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ: Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med, 124: 966-978, 2000.
3. Barbati A, Cosmi EV, Sidoni A, Collini P, Porpora MG, Ferri I, Luthy M, Lauro V, Bucciarelli E: Value of c-erbB-2 and p53 oncoprotein co-overexpression in human breast cancer. Anticancer Res, 17: 401-406, 1997.
4. Visscher DW, Castellani R, Wykes SM, Sarkar FH, Hussain ME: Concurrent abnormal expression of ERBB-2, EGFR, and p53 genes and clinical disease progression of breast carcinoma. Breast Cancer Res Treat, 28: 261-266, 1993.
5. Wiltschke C, Kindas-Muegge I, Steininger A, Reiner A, Reiner G, Preis PN: Coexpression of HER-2/neu and p53 is associated with a shorter disease-free survival in node-positive breast cancer patients. J Cancer Res Clin Oncol, 120: 737-742, 1994.
6. Nakopoulou LL, Alexiadou A, Theodoropoulos GE, Lazaris AC, Tzonou A, Keramopoulos A: Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer. J Pathol, 179: 31-38, 1996.
7. Bertheau P, Steinberg SM, Merino MJ: c-erbB-2, p53 and nm23 gene product expression in breast cancer in young women: immunohistochemical analysis and clinicopathologic correlation. Hum Pathol, 29: 323-329, 1998.
8. Beenken SW, Grizzle WE, Crowe DR, Conner MG, Weiss HL, Sellers MT, Krontiras H, Urist MM, Bland KI: Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53. Ann Surg, 233: 630-638, 2001.
9. Tsutsui S, Ohno S, Murakami S, Kataoka A, Kinoshita J, Hachitanda Y: Prognostic significance of the coexpression of p53 and c-erbB-2 in breast cancer. Am J Surg, 185: 165-167, 2003.
10. Bull SB, Ozcelik H, Pinnaduwage D, Blackstein ME, Sutherland DAJ Prichard KI, Tzontcheva AT, Sidlofsky S, Hanna WM, Qizilbash AH, Tweeddale ME, Fine S, McCready DR, Andrulis IL: The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. J Clin Oncol, 22: 86-96, 2004.
11. Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S, Iwase H: Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res, 6: R24-R30, 2004.
12. Pich A, Margaria E, Chiusa L: Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival. J Clin Oncol, 18: 2948-2956, 2000.
13. Jacquemier J, Penault-Llorca F, Viens P, Houvenaeghel G, Hassoun J, Torrente M, Adelaide J, Birnbaum D: Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression. Anticancer Res, 14: 2773-2778, 1994.
14. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L: p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol, 13: 821-830, 1995.
15. Haerslev T, Jacobsen GK: An immunohistochemical study of p53 with correlations to histopathological parameters, c-erbB-2, proliferating cell nuclear antigen and prognosis. Hum Pathol, 26: 295-301, 1995.
16. Menard S, Casalini P, Pilotti S, Cascinelli N, Rilke F, Colnaghi MI: No additive impact on patient survival of the double alteration of p53 and c-erbB-2 in breast carcinoma. J Natl Cancer Inst, 88: 1002-1003, 1996.
17. Reed W, Hannisdal E, Boehler PJ, Gundersen S, Host H, Nesland JM: The prognostic value of p53 and c-erbB-2 immunostaining is overrated for patients with lymph node negative breast cancer. A multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer, 88: 804-813, 2000.
18. Korkolis D, Ardavanis A, Yotis J, Kyroudi A, Gorgoulis V, Kittas C: HER-2/neu overexpression in breast cancer: an immunohistochemical study including correlations with clinicopathologic parameters, p53 oncoprotein and cathepsin-D. Anticancer Res, 21: 2207-2212, 2001.
19. Cavaliere A, Sidoni A, Scheibel M, Bellezza G, Brachelente G, Vitali R, Bucciarelli E: Biopathologic profile of breast cancer core biopsy: is it always a valid method? Cancer Lett, 218: 117-121, 2005.
20. Sidoni A, Cavaliere A, Bellezza G, Scheibel M, Bucciarelli E: Breast cancer in young women: clinicopathological features and biological specificity. Breast, 12: 247-250, 2003.
21. Sidoni A, Cavaliere A, D'Amico GAM, Brachelente G, Bucciarelli E: Biopathological significance of single cell DNA aneuploidy measured by static cytometry in breast cancer. Breast, 10: 325-329, 2001.